Referencias: The public's use and views of GLP-1 drugs, KFF Health Tracking Poll, 2024 Anti-obesity drug market to reach USD 82.55 billion in 2031, exclusive report by coherent market insights, 2025 Why are we still in need for novel anti-obesity medications?, The Lancet Regional Health - Europe, 2024 Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine, 2021 High protein intake stimulates postprandial GLP1 and PYY release, PubMed, 2013 Closing Americas fiber intake gap, PubMed, 2016 Recent achievements and future directions of anti-obesity medications, The Lancet Regional Health - Europe, 2024 Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota, Nature Metabolism, 2024 GLP-1 Receptor agonists significantly impair taste function, Science Direct, 2025 Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study, National Library of Medicine, 2025 Las marcas y logotipos INGREDION, VITESSENCE y HOMECRAFT son marcas registradas del grupo de empresas Ingredion
Ngi t 7-15 tui dng 1 vin mi ln, ngy s dng 2 ln
Variants in FTO , GLP1R (the GLP-1 receptor gene), MC4R , and TCF7L2 map the metabolic terrain a compound is prescribed into
Second, because its secondary exposure metric quantified APAP use through prescription dispensations, it does not account for over-the-counter APAP use
This initiative aims to bypass the high costs and shortages associated with brand-name drugs like Ozempic and Wegovy
